**1. General facts on colorectal cancer**

Over the past decades, significant progress has been made in clinical and preclinical sciences. It has been lucky to see the integration of multiple discovery disciplines in science and medicine to push the limits of diagnosis and treatment of disorders that can affect many diseases. However, cancer is an exceptional disease that is relatively intractable and despite the multiple discovery disciplines scholarly. Colorectal cancer (CRC) is the third most common cause of cancer-associated mortality worldwide. According to the data from the National Center for Health Statistics, about 135,000 people are estimated to undergo chemotherapy with CRC in the USA each year, and approximately 50,000 people succumb to the disease annually [1]. Additionally, estimation of the Global Cancer Control project indicated that nearly 2 million people worldwide were diagnosed every year [2]. Wellknown option targeting CRC treatment is currently suggested surgical resection preferentially, and if the tumor progression is in an advanced stage, it does require combination with chemotherapy and/or radiation therapy. There is no doubt that surgery, chemotherapy, and radiation therapy are the best choices for treating CRC, even therapeutic efficiency is improving. However, it is still insufficient to reach a convincing level except for the case of early detection; therefore the craving for better potential therapies is still ongoing.
